Julian Adams
Chairman at ELICIO THERAPEUTICS, INC.
Net worth: 24 806 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Robert Connelly | M | 63 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 6 years |
Thomas Bures | M | 49 | 7 years | |
Robert Ruffolo | M | 74 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 6 years |
Carol Ashe | F | 66 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 4 years |
Anthony Evnin | M | 83 |
Infinity Discovery, Inc.
| 23 years |
Norman Selby | M | 71 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 21 years |
Seth Tasker | M | 45 | 16 years | |
James Geraghty | M | 69 | 7 years | |
Megan Filoon | F | - | 1 years | |
Christopher Haqq | M | 58 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 5 years |
Ann J. Barbier | M | 59 | 6 years | |
Allen Nissenson | M | 77 | 4 years | |
Annette Matthies | M | 47 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 3 years |
Peter DeMuth | M | 38 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 7 years |
Janice Fukakusa | F | 69 |
Princess Margaret Cancer Foundation
| - |
Esther Welkowsky | F | - |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 4 years |
Michael Burns | M | - |
Princess Margaret Cancer Foundation
| 6 years |
Christopher Kiritsy | M | 59 | 8 years | |
Karen Wilson | F | 61 | 1 years | |
Yekaterina Chudnovsky | F | 39 | 2 years | |
Mary Coelho | F | 62 | 1 years | |
Angelika Amon | F | - |
Stand Up To Cancer
Stand Up To Cancer Miscellaneous Commercial ServicesCommercial Services Stand Up To Cancer (SU2C) is a non-profit organization that raises funds to accelerate cancer research and bring new therapies to patients quickly. SU2C is based in Los Angeles, CA. Established in 2008 by media and entertainment leaders, SU2C engages the public in supporting a collaborative model of cancer research, increasing awareness about cancer prevention, and highlighting progress in the fight against the disease. The organization has over 3,000 scientists from more than 210 institutions involved in SU2C-funded research projects. The American Association for Cancer Research (AACR) and a scientific advisory committee oversee grants administration and provide expert review of research progress. | - |
John Glaspy | M | - |
Stand Up To Cancer
Stand Up To Cancer Miscellaneous Commercial ServicesCommercial Services Stand Up To Cancer (SU2C) is a non-profit organization that raises funds to accelerate cancer research and bring new therapies to patients quickly. SU2C is based in Los Angeles, CA. Established in 2008 by media and entertainment leaders, SU2C engages the public in supporting a collaborative model of cancer research, increasing awareness about cancer prevention, and highlighting progress in the fight against the disease. The organization has over 3,000 scientists from more than 210 institutions involved in SU2C-funded research projects. The American Association for Cancer Research (AACR) and a scientific advisory committee oversee grants administration and provide expert review of research progress. | - |
William Bro | M | - |
Stand Up To Cancer
Stand Up To Cancer Miscellaneous Commercial ServicesCommercial Services Stand Up To Cancer (SU2C) is a non-profit organization that raises funds to accelerate cancer research and bring new therapies to patients quickly. SU2C is based in Los Angeles, CA. Established in 2008 by media and entertainment leaders, SU2C engages the public in supporting a collaborative model of cancer research, increasing awareness about cancer prevention, and highlighting progress in the fight against the disease. The organization has over 3,000 scientists from more than 210 institutions involved in SU2C-funded research projects. The American Association for Cancer Research (AACR) and a scientific advisory committee oversee grants administration and provide expert review of research progress. | - |
Jack Fleischmann | M | - |
Princess Margaret Cancer Foundation
| - |
Donald R. Sadoway | M | - |
Massachusetts Institute of Technology
| 46 years |
Fiorella Kostoris | F | 79 |
Massachusetts Institute of Technology
| 44 years |
Brian Piekos | M | 49 | 1 years | |
Andrew Hoffman | M | 62 |
Princess Margaret Cancer Foundation
| 8 years |
Andrew Irvine | M | 72 |
Princess Margaret Cancer Foundation
| 8 years |
M. Marianne Harris | F | 66 |
Princess Margaret Cancer Foundation
| - |
Annie Ropar | F | - |
Princess Margaret Cancer Foundation
| 7 years |
Mary-Alice Vuicic | F | 56 |
Princess Margaret Cancer Foundation
| 10 years |
John D. Joannopoulos | M | - |
Massachusetts Institute of Technology
| 46 years |
Stuart Waugh | M | - |
Princess Margaret Cancer Foundation
| 10 years |
Jochen Tilk | M | 60 |
Princess Margaret Cancer Foundation
| - |
Richard Elgin Rooney | M | - |
Princess Margaret Cancer Foundation
| 7 years |
Joy Seymour | F | - | 2 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Lawrence Bloch | M | 58 | 11 years | |
Richard Kogan | M | 81 | 21 years | |
Jaren Madden | F | - | 7 years | |
Ofer Gonen | M | 50 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 7 years |
Gerald Quirk | M | 56 | 6 years | |
Darlene Deptula-Hicks | F | 66 | - | |
Franklin H. Moss | M | 75 |
Infinity Discovery, Inc.
| 10 years |
Christopher M. Lindblom | M | 52 | 8 years | |
Eric S. Lander | M | 67 |
Infinity Discovery, Inc.
| 15 years |
Joshua D. Hamermesh | M | 51 | 3 years | |
Allan Reine | M | 49 | 2 years | |
Steven Kafka | M | 54 | 6 years | |
Yael Margolin | M | 70 | 14 years | |
Mark A. Clements | M | - |
Massachusetts Institute of Technology
| 3 years |
Thomas Lynch | M | 63 | 5 years | |
Vito Palombella | M | 61 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 14 years |
Patrick Lee | M | 67 |
Infinity Discovery, Inc.
| 11 years |
Assaf Segal | M | 51 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | 1 years |
Steven Holtzman | M | 70 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | 18 years |
Yoo-Hwan Jang | M | 69 |
Massachusetts Institute of Technology
| 3 years |
Heather DiVecchia | F | - | 6 years | |
Lance Thibault | M | 58 | 1 years | |
James Tananbaum | M | 60 |
Infinity Discovery, Inc.
| 11 years |
Shawn Tomasello | F | 65 | 5 years | |
Samuel Minzberg | M | 67 |
McGill University
| 11 years |
Abbey Jenkins | F | - | 2 years | |
Jolie Siegel | F | 48 | 2 years | |
Beth A. Marcus | M | - |
Massachusetts Institute of Technology
| 5 years |
Peter Zieve | M | 70 |
Massachusetts Institute of Technology
| 3 years |
Glenn Ives | M | 62 |
Princess Margaret Cancer Foundation
| 9 years |
Jocelyn E. Scott | F | - |
Massachusetts Institute of Technology
| 4 years |
Tom A. Stefanick | M | - |
Massachusetts Institute of Technology
| 5 years |
Ruben Ojeda | M | - |
Massachusetts Institute of Technology
| 6 years |
Meryl Zausner | F | 67 | 3 years | |
On-kwok Li | M | 69 |
Massachusetts Institute of Technology
| 3 years |
Terence S. Orstlan | M | - |
McGill University
| 6 years |
Steven C. Webster | M | 67 |
Massachusetts Institute of Technology
| 5 years |
J. Wargo | M | 69 |
Massachusetts Institute of Technology
| 6 years |
Scott Kapnick | M | - | 8 years | |
José Baselga | M | 65 | 3 years | |
Chau Khuong | M | 48 | 3 years | |
Paul Arnison | M | - |
McGill University
| 6 years |
Caroline Dorsa | F | 64 | 22 years | |
Richard Bagley | M | 80 |
ProScript, Inc.
ProScript, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million. | 4 years |
John Hector McArthur | M | 90 | 8 years | |
Kenneth Moch | M | 69 | 8 years | |
Brian Jacobs | M | 63 |
Massachusetts Institute of Technology
| 5 years |
Tom Maniatis | M | 80 |
ProScript, Inc.
ProScript, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million. | - |
John Robert Chisholm | M | - |
Massachusetts Institute of Technology
| 7 years |
Ian Smith | M | 58 | 11 years | |
Marino Carol | F | - | 8 years | |
Kenneth Bartizal | M | 72 | 20 years | |
Paul Alofs | M | - |
Princess Margaret Cancer Foundation
| 15 years |
Perry Ha | M | 62 |
Massachusetts Institute of Technology
| 6 years |
Bert Richards | M | - |
Massachusetts Institute of Technology
| 5 years |
Brian E. Foody | M | - |
Massachusetts Institute of Technology
| 5 years |
Daphne Karydas | F | 49 |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | - |
Jon Hirschtick | M | - |
Massachusetts Institute of Technology
| 5 years |
Don Shulsinger | M | - |
Massachusetts Institute of Technology
| 6 years |
Huw Nash | M | 57 | 12 years | |
Montgomery Alger | M | 67 |
Massachusetts Institute of Technology
| 5 years |
Zaurie Zimmerman | F | - |
Massachusetts Institute of Technology
| 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 78 | 78.00% |
Canada | 16 | 16.00% |
Israel | 9 | 9.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Julian Adams
- Personal Network